Yazar "Yoldas, T." seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Can polyglactin mesh be used for prevention of seroma after mastectomy: an experimental study(Springer Wien, 2014) Yeniay, L.; Unalp, O. V.; Uguz, A.; Unver, M.; Karaca, A. C.; Sezer, T. O.; Yoldas, T.; Demir, H. B.; Zekioglu, O.; Kapkac, M.; Yilmaz, R.Background Seroma formation is still a common problem in breast surgery. Seroma formation is associated with morbidity and financial loss. Fibrin glue was used in several studies for solution, but the results were controversial. On the other hand surgical meshes are promising to prevent the seroma formation. Methods A total of 48 female Sprague-Dawley rats were randomly assigned to four groups. Each underwent radical mastectomy, axillary lymph node dissection, and disruption of the dermal lymphatic vessels. Group 1 is the control group (n = 12). In group 2 (n = 12), 1 x 1 cm polyglactin 910 mesh (Vicryl, Ethicon Johnson&Johson USA) is placed over the chest wall under the skin flaps prior to closure. The animals in group 3 received 0.5 mL fibrin glue (Baxter Healthcare Ltd. United Kingdom) topically throughout the wound before the closure (n = 12). The animals in group 4 (n = 12) received 0.5 mL fibrin glue topically throughout the wound, and 1 x 1 cm polyglactin 910 mesh is placed under the skin flaps prior to the closure. Full thickness tissue samples from both the chest wall and the skin were harvested. The harvested tissue samples were evaluated by a single pathologist in a blind fashion. Results The mean seroma volume of the control group was 1.536 mL whereas the mean seroma volume of the groups 2, 3, and 4 were 1.189, 0.438, and 0.556 respectively. Mean seroma volume was significantly lower, adhesion index and foreign body reaction were higher in group 4. Conclusion Although various studies show controversial results to prevent the seroma formation. This experimental study is an evidence that fibrin glue and polyglican mesh reduce seroma with increasing inflammatory reaction.Öğe Evaluation of right sided and left sided colon tumors: review of 963 cases(Springer, 2014) Yildirim, F.; Doganavsargil, B.; Sezak, M.; Yoldas, T.; Tuncyurek, M.Öğe FACTORS CD10, CYTOKERATIN 19 AND STAGING-GRADING SYSTEMS IN PREDICTING THE PROGNOSIS OF PANCREATIC NEUROENDOCRINE TUMORS (PNET)(Editura Acad Romane, 2012) Uguz, A.; Unalp, O. V.; Yeniay, L.; Farajov, R.; Yoldas, T.; Sezer, T. O.; Ipek, N. Y.; Nart, D.; Yilmaz, F.; Sozbilen, M.; Coker, A.Objective. This study was undertaken to examine prognostic factors in patients with pancreatic neuroendocrine tumors (PNET) undergoing surgical treatment to evaluate the prognostic value of recently introduced immunohistochemical staining methods of CD10 and cytokeratin 19. Materials and Methods. Tumors were classified on the basis of 2004 WHO Classification Guidelines and European Neuroendocrine Tumor Society (ENETS) grading system. Immunohistochemical staining with Ki-67, CD10 and cytokeratin 19 was performed. Results. A total of 36 patients with a mean age of 53.7 +/- 12.0 years were included. Overall, 33 patients had a long-term follow-up with 10 patients (30.3%) experiencing recurrence. Seven patients (21.1%) died. Clinical parameters that were associated with recurrence included liver metastasis at the time of surgery and extra-pancreatic invasion (p < 0.005). Positive surgical margins, extra-pancreatic invasion, and multi-focal disease were associated with reduced survival (p < 0.05). In addition, there was an association between survival and WHO 2004 classification (p < 0.05). Conclusions. Although vascular and peripancreatic invasion showed increased risk of recurrence, they were unrelated to survival. Of the histopathological examinations, Ki-67 and mitotic activity showed a correlation with both recurrence and survival, while immunohistochemical staining with cytokeratin 19 and CD 10 did not provide adequate prognostic information.Öğe A mixed neuroendocrine tumor loceted in appendix vermiformis: "Goblet cell carsinoid''(Springer, 2012) Cinar, E. Ayhan; Sarsik, B.; Sezak, M.; Yoldas, T.; Doganavsargil, B.Öğe The plasma cells density in pararectal lymph nodes of patients with rectal cancer after neoadjuvant therapy(Springer, 2012) Sezak, M.; Ozsan, N.; Pehlivanoglu, B.; Ozkok, S.; Yoldas, T.; Daganavsargil, B.Öğe Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer(Wiley, 2018) Akgun, E.; Caliskan, C.; Bozbiyik, O.; Yoldas, T.; Sezak, M.; Ozkok, S.; Kose, T.; Karabulut, B.; Harman, M.; Ozutemiz, O.Background: The optimal timing of surgery following preoperative chemoradiotherapy (CRT) is controversial. This trial aimed to compare pathological complete response (pCR) rates obtained after an interval of 8weeks or less versus more than 8weeks. Methods: Patients with locally advanced rectal adenocarcinoma situated within 12cm of the anal verge (T3-4 or N+ disease) were randomized to undergo total mesorectal excision (TME) within 8weeks (classical interval, CI group) or after 8weeks (long interval, LI group) following CRT. Results: Among the 327 included patients (CI 160, LI 167), the pCR rate was significantly higher in the LI group than in the CI group (100 versus 186 per cent; P=0027). The highest pCR rate (29 percent) was observed between 10 and 11weeks. There was statistically significant disease regression in the LI group, with better stage (P=0004) and T category (P=0001) than in the CI group. There was no significant difference in surgical quality (rates of tumour-positive margins, TME quality, anastomotic leakage and intraoperative perforation) between the groups. The overall morbidity rate was 225 per cent in the CI group and 198 per cent in the LI group (P=0307). Regression analysis including sex, age, clinical stage, tumour location, tumour differentiation, TME quality, concomitant chemotherapy and interval to surgery revealed no statistically significant predictors of pCR. Conclusion: Disease regression and pCR rate are increased with an interval between CRT and surgery exceeding 8weeks. Registration number: NCT03287843.
